PAVmed (PAVM) Amortization of Deferred Charges (2017 - 2018)

PAVmed's (PAVM) quarterly Amortization of Deferred Charges came in at $505848.0 in Q3 2018, up 65.45% quarter-over-quarter from $305734.0 in Q2 2018.

PAVmed (PAVM) Amortization of Deferred Charges (2017 - 2018) Analysis & Trends

PAVmed's Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $505848.0 for Q3 2018.

On a quarterly basis, Amortization of Deferred Charges changed N/A year-over-year to $505848.0 in Q3 2018; TTM through Sep 2018 was $1.3 million, a N/A change from a year earlier, with the FY2017 full-year figure at $347601.0, changed N/A from the prior year.
Amortization of Deferred Charges grew to $505848.0 in Q3 2018 per PAVM's latest filing, from $305734.0 in the prior quarter.
Across five years, Amortization of Deferred Charges topped out at $505848.0 in Q3 2018 and bottomed at $172959.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	181.51 Bn	174.22 Bn	6.27 Bn
2	Stryker	128.20 Bn	125.32 Bn	3.81 Bn
3	Medtronic	107.69 Bn	98.47 Bn	6.41 Bn
4	Boston Scientific	68.05 Bn	66.59 Bn	3.61 Bn
5	Edwards Lifesciences	47.52 Bn	43.85 Bn	1.29 Bn
6	GE HealthCare Technologies	28.46 Bn	26.17 Bn	1.98 Bn
7	Dexcom	28.25 Bn	27.13 Bn	750.30 Mn
8	Smith & Nephew	26.73 Bn	26.15 Bn	-
9	Koninklijke Philips	25.31 Bn	22.19 Bn	2.07 Bn
10	PAVmed	11.18 Mn	9.64 Mn	-4,000.00

Download Data